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AbstrAct
Background FOLFOXIRI plus bevacizumab is considered 
a standard option in the upfront treatment of clinically 
selected patients with metastatic colorectal cancer 
irrespective of RAS and BRAF molecular status. The 
randomised MACBETH and VOLFI studies showed that 
a modified FOLFOXIRI regimen in combination with 
cetuximab or panitumumab, respectively, achieved high 
therapeutic activity in RAS and BRAF wild-type patients 
with an acceptable toxicity profile. Drawing from these 
considerations, we designed TRIPLETE study aiming 
at comparing two different chemotherapy backbones 
(mFOLFOXIRI or mFOLFOX6) in combination with 
panitumumab in the first-line treatment of patients with 
RAS and BRAF wild-type metastatic colorectal cancer.
Methods This is a prospective, open-label, multicentre 
phase III trial in which initially unresectable and previously 
untreated RAS and BRAF wild-type metastatic colorectal 
cancer patients are randomised to receive a standard 
treatment with mFOLFOX6 plus panitumumab or an 
experimental regimen with modified FOLFOXIRI (irinotecan 
150 mg/m2, oxaliplatin 85 mg/m2, L-leucovorin 200 mg/
m2, 5-fluoruracil 2400 mg/m2 48-hour continuous 
infusion) plus panitumumab up to 12 cycles, followed by 
panitumumab plus 5-fluorouracil and L-leucovorin until 
disease progression. The primary endpoint is overall 
response rate according to RECIST 1.1 criteria.
Discussion The relative benefit of chemotherapy 
intensification when using an anti-EGFR-based regimen 
in molecularly selected patients is unknown; TRIPLETE 
study aims at filling this gap of knowledge. The study 
is sponsored by the Gruppo Oncologico Nord Ovest 
Cooperative Group and is currently ongoing at 42 Italian 
centres.
Clinical trial information NCT03231722.
IntroDuCtIon
Selecting the most appropriate first-line treat-
ment is a challenging issue in the management 
of metastatic colorectal cancer (mCRC). The 
paramount importance of this choice lies in 
the role of the upfront treatment in achieving 
disease control, thus obtaining symptoms’ 
relief, allowing further locoregional and 
systemic interventions and, even more rele-
vantly, providing the unique opportunity to 
cure some metastatic patients.1 
A growing amount of drugs is indicated 
for the first-line treatment of mCRC and, in 
the absence of contraindications, the associa-
tion of a biological agent to a chemotherapy 
doublet is a standard upfront choice. Never-
theless, emerging evidence highlights the 
possibility to further personalise the treat-
ment by modulating the intensity of the 
chemotherapy backbone from one- drug 
to three- drug regimens according to treat-
ment’s objective, patient’s characteristics and 
tumour biology.2 3
To this regard, the phase III randomised 
TRIBE study evaluated the combination of 
bevacizumab with the three-drug regimen 
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FOLFOXIRI (5-fluorouracil, oxaliplatin and irinotecan) 
or the doublet FOLFIRI (5-fluorouracil and irinotecan). 
The trial met its primary endpoint reporting significantly 
longer progression-free survival (PFS; 12.1 vs 9.7 months, 
HR: 0.75, p=0.003) in favour of the triplet. A signifi-
cant advantage in terms of overall survival (OS; 29.8 vs 
25.8 months, HR: 0.80, p=0.030) and objective response 
rate (ORR; 65% vs 53%, p=0.006) was also evident. The 
triplet was associated with increased grade 3 and 4 neut-
ropaenia, diarrhoea and stomatitis but no higher inci-
dences of febrile neutropaenia, serious adverse events or 
treatment-related deaths were reported.4 5 Other phase II 
randomised trials with the use of FOLFOXIRI plus bevaci-
zumab were conducted, and consistent efficacy and safety 
results were achieved.6 Based on these results, the triplet 
FOLFOXIRI plus bevacizumab is now regarded by all 
major guidelines as a safe and efficacious first-line thera-
peutic option for selected patients with mCRC.2 3 7
Also the combination of FOLFOXIRI with an anti-EGFR 
monoclonal antibody has been investigated in some phase 
II trials, pointing out remarkable activity results, translating 
into high secondary resection rates (table 1),8–14 at the price 
of a substantial increase in chemotherapy-related toxicities, 
in particular grades 3 and 4 diarrhoea. A single-arm phase II 
study by Gruppo Oncologico Nord Ovest (GONO) assessed 
the activity and safety of the combination of panitumumab 
with a modified schedule of FOLFOXIRI (irinotecan was 
administered at 150 instead of 165 mg/m2) in a highly 
molecularly selected population of 37 patients with unresect-
able KRAS/NRAS/HRAS/BRAF wild-type (wt) disease. Based 
on the occurrence of severe diarrhoea and mucositis in two 
of the first three patients enrolled, the study was amended 
to reduce the dosage of the 48-hour continuous infusion of 
5-fluorouracil (5-FU) from 3200 mg/m2 to 2400 mg/
m2. After the amendment, the most common grades 3–4 
adverse events were neutropaenia (48%), diarrhoea (35%), 
asthenia (27%), stomatitis (14%) and skin rash (14%).12 
More recently, the phase II randomised MACBETH study 
tested the combination of cetuximab plus a modified 
FOLFOXIRI regimen (mFOLFOXIRI: irinotecan: 130 mg/
m2 day 1, oxaliplatin: 85 mg/m2 day 1, L-Leucovorin (LV) 
200 mg/m2 day 1, 5-FU 2400 mg/m2 48-hour continuous 
infusion) in 116 patients with RAS/BRAF-wt mCRC. The 
safety profile was acceptable (31% grades 3–4 neutropaenia, 
18% grades 3–4 diarrhoea, 6% grades 3–4 stomatitis, 16% 
grades 3–4 skin rash and 3% febrile neutropaenia) and reas-
suring results about the feasibility of this combination were 
provided. Encouraging activity data emerged, with 72% and 
91% ORR and disease control rate (DCR), respectively. In 
addition, 76% of patients achieved early tumour shrinkage 
(ETS), and the median depth of response (DoR) was 53%; 
R0 resection rate was 28% in the overall population and 
50% in the liver-only subgroup. Four months of mFOLF-
OXIRI plus cetuximab followed by cetuximab maintenance 
achieved a median PFS of 10.1 months and an OS of 33.2 
months.14 Therefore, data from MACBETH confirmed the 
feasibility of the modified triplet plus an anti-EGFR mono-
clonal antibody and remarked the notable activity of this 
treatment translating into a high secondary resection rate.
Another recent phase II study, VOLFI, that randomised 
96 patients with RAS wt mCRC to receive FOLFOXIRI±pa-
nitumumab, reported high ORR (86% vs 61% with FOLF-
OXIRI, p=0.0096) and DCR (97% vs 79%, p=0.0071) with 
the triplet plus the anti-EGFR. Secondary R0 resection 
rate was 16% in triplet plus anti-EGFR arm versus 9% in 
chemotherapy-only arm in the overall population and 
50% vs 27% in the potentially resectable cohort.13
In spite of encouraging safety and activity results, it 
is not clear whether the intensification of the chemo-
therapy backbone in combination with the anti-EGFR 
Table 1 Trials with anti-EGFR plus triplet chemotherapy in patients with metastatic colorectal cancer
Author n
Molecular 
selection Schedule RR (%)
R0 resection 
rate (%)
Grades 3–4 
diarrhoea (%) mPFS mOS
Garufi et al8 43 No molecular 
selection
Chrono-IFLO+
cetuximab
79 60 94–36 14 months 37 months
Assenat et al9 42 KRAS exon 2 wt FOLFIRINOX+
cetuximab
81 Not reported 52 9.5 
months
24.7 months
Folprecht et al10 20 No molecular 
selection
mFOLFOXIRI+
cetuximab
75 Not reported 25 16 months 33 months
Saridaki et al11 30 KRAS exon 2 wt FOLFOXIRI+
cetuximab
70 37 53 10.2 
months
30.3 months
Fornaro et al12 37 KRAS, 
NRAS and BRAF 
wt
mFOLFOXIRI+
panitumumab
89 35 33 11.3 
months
Not reached
Geissler et al13 30 RAS wt mFOLFOXIRI+
panitumumab
86 16 Not reported 10.8 
months
Not reported
Cremolini et al14 143 KRAS exon 2 
then, RAS and 
BRAF wt
mFOLFOXIRI+
cetuximab
72 28 18 10.1 
months
33.2 months
mPFS, median progression free survival; mOS, median overall survival; RR, response rate.
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may be beneficial and to what extent in properly selected 
patients. This gap of knowledge might be filled only 
by a phase III study. Drawing from this evidence, we 
designed the TRIPLETE study, a phase III randomised 
trial of first-line mFOLFOXIRI plus panitumumab versus 
mFOLFOX6 plus panitumumab in patients with RAS and 
BRAF wt unresectable mCRC.
MethoDs/DesIgn
study design
The present study is a prospective, open-label, multi-
centre phase III randomised trial in which initially unre-
sectable and previously untreated patients with RAS and 
BRAF wt mCRC are randomised in a 1:1 ratio to receive 
panitumumab plus mFOLFOX6 (arm A, standard treat-
ment) or panitumumab plus mFOLFOXIRI (arm B, 
experimental arm) every 14 days up to 12 cycles, followed 
by panitumumab plus 5-FU/LV as maintenance in both 
arms until disease progression, unacceptable adverse 
events or consent withdrawal (figure 1).
The feasibility of surgical radical resection of residual 
metastases in responsive patients is evaluated every 8 
weeks. In the case of secondary resection of metastases, 
a postoperative therapy with the same chemotherapy 
regimen received before resection plus panitumumab is 
planned up to a total duration (preoperative plus postop-
erative treatment) of 12 cycles (figure 2). The postopera-
tive treatment should start not earlier than 4 weeks after 
surgery.
study objectives and endpoints
The primary objective of this trial is to compare the activity 
of panitumumab in combination with mFOLFOX6 or with 
mFOLFOXIRI in patients with RAS and BRAF wt mCRC 
in terms of ORR according to RECIST 1.1 criteria.15 
ORR is defined as the percentage of patients achieving a 
complete response (CR) or partial response (PR) during 
the study treatment period.
Secondary objectives of this study are to compare the 
two proposed treatments in terms of safety profile, PFS, 
OS, centrally assessed ORR, ETS, DoR and R0 resection 
rate.
PFS is defined as the time from randomisation to the 
first disease progression or death, whichever occurs first; 
Figure 1 Study design. 5-FU, 5-fluorouracil; ECOG PS, Eastern Cooperative Oncology Group Performance Status; LV, 
L-Leucovorin; PD, disease progression.
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OS is defined as the time from randomisation to the 
date of death due to any cause; centrally assessed ORR 
is defined as the percentage of patients relative to the 
total of enrolled subjects, achieving a CR or PR based on 
central re-evaluation of CT scan images; ETS is defined 
as the rate of patients, relative to the total of the enrolled 
subjects, achieving a ≥20% decrease in the sum of diam-
eters of RECIST target lesions at week 8 compared with 
baseline; DoR is defined as the relative change in the sum 
of longest diameters of RECIST target lesions at the nadir, 
in the absence of new lesions or progression of non-target 
lesions, when compared with baseline; R0 resection rate is 
defined as the percentage of patients, relative to the total 
of enrolled subjects, undergoing secondary R0 resection 
of metastases.
statistical design
The primary analysis of ORR will be performed in the 
intention-to-treat population. The proportion of patients 
with a best overall response of CR or PR with its 95% CI 
will be reported for each arm. The χ2 test for heteroge-
neity and the OR will be used for comparing the distri-
butions of best overall response among the treatment 
groups. Patients are stratified according to the following 
factors: ECOG Performance Status (ECOG PS) (0 vs 1–2), 
primary tumour location (right [from cecum to trans-
verse colon] vs left [from splenic flexure to rectum]) 
and spread of metastatic disease (liver limited vs no 
liver limited). The stratified analysis in the intention-to-
treat population will be presented as primary analysis.
Under the assumption of a ORR in the control group 
equal to 60%, based on the results of the registrative 
trial of panitumumab in association with FOLFOX,16 a 
total sample size of 432 cases, randomised in a 1:1 ratio, 
provides approximately 90% power to a two-sided χ2 test 
for heterogeneity at the 0.05 significance level, in order 
to detect a ≥15% difference in ORR between the two 
treatment arm.
The Kaplan-Meier method will be used to performed 
survival analyses. Log-rank tests stratified by the same 
factors as used for randomisation will also be performed, 
as well as multivariable models including all the signif-
icant baseline variables. The median event times and 
corresponding two-sided 95% CIs for the median will 
be provided. A secondary analysis of all primary and 
secondary endpoints will be performed in the centrally 
assessed RAS/BRAF wt population.
study population
The study has been approved by 58 ethics commit-
tees and is currently ongoing at 42 Italian oncology 
units. Consistent with previous FOLFOXIRI-based trials 
conducted by the GONO group, only patients aged <70 
years with ECOG PS ≤2, or aged 71–75 years with ECOG 
PS 0, are eligible. Main inclusion criteria are: the availa-
bility of a tumour tissue sample (primary tumour and/or 
metastatic sites), RAS (codons 12, 13, 59, 61, 117 and 146 
of KRAS and NRAS genes) and BRAF (V600E mutation) 
wt status of primary colorectal cancer or related metas-
tasis, at least one measurable lesion according to RECIST 
1.1, adequate liver, renal and bone marrow function. 
Previous oxaliplatin-based adjuvant chemotherapy is not 
permitted; adjuvant fluoropyrimidine monotherapy is 
allowed only if more than 6 months have elapsed between 
the end of adjuvant therapy and disease relapse. Other 
exclusion criteria are: previous treatment with anti-EGFR 
Figure 2 Postoperative treatment in case of secondary resection of metastases.
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inhibitors, symptomatic peripheral neuropathy >1 
according to NCI-CTCAE V.4.017 and contraindications 
to study drugs.
study procedures
Patients randomised in arm A (standard arm) receive 
mFOLFOX6 plus panitumumab (panitumumab 6 mg/
kg, oxaliplatin 85 mg/m2, LV200 mg/m2, 5-FU 400 mg/
m2 intravenous bolus, 5-FU 2400 mg/m2 48-hour contin-
uous infusion) every 2 weeks for a maximum of 12 cycles.
Patients randomised in arm B (experimental arm) 
receive mFOLFOXIRI plus panitumumab (panitumumab 
6 mg/kg, irinotecan 150 mg/m2, oxaliplatin 85 mg/m2, 
LV 200 mg/m2, 5-FU 2400 mg/m2 48-hourh continuous 
infusion) every 2 weeks for a maximum of 12 cycles. If 
no progression occurs, maintenance with 5-FU/LV plus 
panitumumab is administered biweekly in both arms at 
the same dose used at the last cycle of the induction treat-
ment until disease progression, unacceptable toxicity or 
patient’s refusal. The continuation of panitumumab until 
disease progression is recommended also if 5-FU is inter-
rupted because of adverse events, patient’s refusal or at 
investigator’s choice.
The application of skin moisturisers, topical steroid 
(1% hydrocortison cream) and sunscreen protections 
is suggested in order to prevent skin acne-like rash. In 
addition, pre-emptive treatment with doxycycline 100 mg 
daily for 1 week starting from day 1 of cycle 1 and then in 
alternate cycles is recommended.
RAS and BRAF testing is locally or centrally performed 
at investigator’s choice. The independent central reas-
sessment of RAS and BRAF mutational status by means 
of MALDI-TOF MassArray (Sequenom) is planned.18 19 
Disease assessment is performed every 8 weeks by means 
of CT-scan.
safety
All adverse events observed during the study treatment 
period are properly registered in the subjects’ medical 
records and in electronic case report forms. All serious 
adverse events (SAEs), that is, fatal or life-threatening 
adverse events or those requiring hospitalisation or 
resulting in persistent or significant disability/incapacity 
should be notified within 24 hours by the investigator to 
the sponsor according to local procedures, statutes and 
the European Clinical Trial Directive (when applicable). 
The sponsor will medically review all SAEs and is respon-
sible for their notification to the appropriate ethics 
committees, competent authorities and participating 
Investigators.
translational analyses
A wide programme of translational analyses is planned. 
The availability of tissue specimens (primary tumour or 
metastatic site) is mandatory for study entry. Tissue speci-
mens are collected for the central assessment of RAS and 
BRAF status and for further molecular analyses. In the 
case of secondary resection of metastases, the collection 
of newly available specimens is required. Also blood and 
plasma samples are collected at baseline, at every CT 
scan performed during induction and at first evidence of 
disease progression. In the case of secondary resection of 
metastases, plasma samples will be collected also within 
1 month before and after surgery, respectively.
ethics and regulatory considerations
The procedures set out in the present study respect the 
Good Clinical Practice guidelines and the guiding prin-
ciples detailed in the Declaration of Helsinki. The study 
is also carried out in keeping with applicable local law(s) 
and regulation(s).
It was registered in the EUDRACT database (EUDRACT 
NUMBER 2016-004394-40) in October 2016 and at  clin-
icaltrials. gov (NCT03231722) in July 2017. Written 
informed consent to study procedures must be provided 
by all candidate patients before the enrolment.
DIsCussIon
Doublets plus anti-EGFR are standard options for the 
upfront treatment of patients with RAS/BRAF wt mCRC. 
While phase II trials suggest interesting activity results 
with triple chemotherapy regimens plus an anti-EGFR, 
the added value of intensifying the chemotherapy back-
bone from doublets to the triplet, when using an anti-
EGFR as upfront targeted agent, has never been esti-
mated. TRIPLETE study aims at filling this current gap 
of knowledge.
Some key points of the trial design deserve consider-
ation. First, with regard to patients’ inclusion criteria, 
primary tumour location was chosen as a stratification 
factor, based on the clear negative prognostic impact 
of right-sidedness20 21 but not as a selection factor. In 
fact patients with right-sided primary tumours were not 
excluded from this trial. Although recognising the lower 
sensitivity to anti-EGFRs of right-sided versus left-sided 
tumours when using a chemotherapy doublet,22 23 the 
lack of regulatory restrictions to the use of anti-EGFRs in 
right-sided tumours, as well as the lack of evidence about 
the usefulness of an intensified chemotherapy backbone 
in combination with the anti-EGFR in this poor-prog-
nosis subgroup, drove this choice. In addition, though 
acknowledging the small sample sizes, in the VOLFI 
study, right-sided tumours achieved an ORR of 60% with 
FOLFOXIRI plus panitumumab as compared with 38% 
with triplet alone.13
Second, in the TRIPLETE study, ORR was chosen as 
primary endpoint. While the choice of OS as primary 
endpoint would have substantially hampered the feasi-
bility of this academic study, the reliability of PFS as a 
surrogate endpoint of OS appears weakened when using 
upfront anti-EGFR-based treatments. However, a signifi-
cant improvement in ORR translating into OS benefit was 
observed in recent phase III trials investigating anti-EG-
FR-containing regimens.16 24 An emblematic example of 
how activity parameters predict OS better than PFS in 
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trials evaluating the efficacy of anti-EGFR agents is the 
FIRE-3 study. In this trial, a clear benefit was demon-
strated in terms of OS in favour of FOLFIRI plus cetux-
imab with respect to FOLFIRI plus bevacizumab with no 
difference in terms of PFS. At the central independent 
radiological evaluation, significantly higher ORR, ETS 
and DoR were reported in RAS wt patients treated with 
cetuximab-based therapy. Also ETS and DoR correlated 
with survival.25 Moreover, as clearly stated by European 
Society for Medical Oncology guidelines, achieving 
cytoreduction is a relevant clinical objective in different 
scenarios of mCRC, including those cases in which the 
secondary resection of metastases is a pursuable objec-
tive and those in which the high tumour burden makes 
response needed in order to improve symptoms or to 
prevent their occurrence.2 To this purpose, the triplet plus 
an anti-EGFR might be a valuable option, as suggested 
by the choice of activity endpoints also in other currently 
ongoing trials evaluating similar regimens (table 2).
Third, in the present study, a 6-month induction phase 
with chemotherapy plus panitumumab, followed by main-
tenance with 5-FU/LV plus panitumumab, is planned in 
both arms. Only a few data are currently available with 
regard to the role of maintenance after an anti-EGFR-
based induction therapy and the ‘best’ maintenance to be 
administered. Our choice was driven by results of trials in 
the ‘chemotherapy-alone era’ underlining the possibility 
to de-potentiate the treatment without compromising 
patients’ prognosis26 27 and by results of two phase II trials, 
respectively showing the non-inferiority of maintenance 
with cetuximab alone versus the full treatment until 
progression28 29 and the feasibility of cetuximab mainte-
nance versus a ‘stop&go’ strategy.29 This decision was also 
recently supported by the presentation of the Japanese 
phase II SAPPHIRE trial where patients not progressing 
after six cycles of FOLFOX plus panitumumab were 
randomised to receive 5-FU/LV and panitumumab as 
maintenance therapy or to continue induction treatment. 
Preliminary data showed similar 9-months PFS (primary 
endpoint of the study) in the two arms, thus supporting 
the use of anti-EGFR plus 5-FU/LV as maintenance in 
order to delay disease progression while preventing the 
occurrence of oxaliplatin-induced neuropathy.30
Finally, in order to improve the adherence to the 
therapy, the administration of doxycycline is recom-
mended in both arms to prevent anti-EGFR-induced 
skin rash. Based on clinical experiences demonstrating 
a reduced incidence of acneiform rash in the case of 
pre-emptive rather than reactive administration of a tetra-
cycline during anti-EGFR-based therapy,31 Multinational 
Association of Supportive Care in Cancer guidelines actu-
ally recommend the pre-emptive use of oral doxycycline 
or minocycline.32
ConClusIons
In the era of personalised medicine, TRIPLETE study will 
throw light on the potential value of a modified schedule 
of FOLFOXIRI plus panitumumab as a valuable upfront 
option for some patients with mCRC, selected on the 
basis of a careful evaluation of patients’ characteristics, 
molecular features and treatment’s objective.
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